8月6日，药捷安康-B盘中上涨5.08%，报12.26港元，成交额4650.54万港元，延续近日强势反弹态势。
消息面上，公司自7月以来密集回购H股，7月内累计回购71.8万股，合计耗资逾700万港元，释放管理层对公司价值的信心。同时，公司于7月24日向67名员工授出约525.89万股H股激励，进一步绑定核心团队利益。管线方面，公司核心产品替恩戈替尼全球注册性III期临床试验已完成入组，TT-00973及TT-01488两款产品II期临床亦先后获批开展，多管线推进提升市场预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.